One purported mechanism of action of cholinesterase inhibitors used in AD is the prevention of glutamate neurotoxicity, an effect that is mediated by nicotinic acetylcholine receptors (nAChRs) and the phosphatidylinositol-3-kinase/Akt metabolic cascade [76]. Here, BCHE is linked to Alzheimer disease.